Literature DB >> 32816157

The impact of multidisciplinary team conferences in urologic cancer in a tertiary hospital.

Miguel Gil1, João Guerra2, Vanessa Andrade2, Mariana Medeiros2, Thiago Guimarães2, Rui Bernardino2, Gil Falcão2, Fernando Calais da Silva2, Luís Campos Pinheiro2.   

Abstract

PURPOSE: Multidisciplinary team (MDT) conferences are currently the standard of care in cancer patients' management. Despite evidence supporting benefits to the majority of malignancies, a paucity of data exists examining the impact in urinary and male genital cancers. This study aims to evaluate the impact of MDT conferences in urologic cancer practice.
METHODS: Clinical plans discussed in urologic MDT conferences in Centro Hospitalar Universitário de Lisboa Central between January 2019 and December 2019 were retrospectively analysed. Clinical plans were categorized as accepted, changed, rejected (cases that had to be re-presented to the MDT because of insufficient staging or administrative issues) or no plan. MDT conferences' impact was assessed according to type of consultation, referral medical specialty and primary tumour type.
RESULTS: 710 clinical plans were discussed at the MDT conferences. 61.8% were accepted, 10.6% were changed, 16.5% were rejected and 11.1% of cases referred to MDT discussion had no defined clinical plan. First consultations had a higher rate of accepted clinical plans (63.4%) versus subsequent consultations (56.4%). Referrals by the urology specialty had the highest rate of acceptances (64.3%). On the stratification by primary tumour site, testicular cancer had the highest acceptance rate (70.3%), whereas bladder cancer had the lowest (47.8%).
CONCLUSIONS: MDT conferences had an important impact in the management of 38.2% of cases. Therefore, all patients with urologic malignancies should be referred to MDT review to ensure optimal clinical care.

Entities:  

Keywords:  Decision-making; Multidisciplinary conference; Multidisciplinary team; Urologic cancer

Mesh:

Year:  2020        PMID: 32816157     DOI: 10.1007/s11255-020-02608-6

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  1 in total

1.  Use of treatment pathway improves neoadjuvant chemotherapy use in muscle-invasive bladder cancer.

Authors:  Kassem S Faraj; Anojan K Navaratnam; Sarah Eversman; Laila Elias; Amit Syal; Mark D Tyson; Erik P Castle
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.